GeoVax Announces Upcoming Presentations at Scientific Conferences

Rhea-AI Summary

GeoVax Labs, Inc. (Nasdaq: GOVX) announced its participation in key scientific conferences showcasing advancements in vaccine development. Notable presentations include:

• National Biotechnology Conference: Dr. Mary Hauser will discuss T cell immunity against evolving SARS-CoV-2 variants on May 11, 2022.
• Genetic Vaccine Development Summit: Dr. Don Diamond will present on the COH04S1 vaccine's development on May 26, 2022.

GeoVax is advancing COVID-19 and cancer immunotherapies, with ongoing Phase 2 trials and innovative vaccine platforms.

ATLANTA, GA, May 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that it will be represented during presentations at the following upcoming scientific conferences.

• 2022 National Biotechnology Conference, Anaheim, CA, May 9-12

On May 11, Mary Hauser, PhD, GeoVax Director, Preclinical Research, will deliver a presentation titled, Strategic Prophylactics to Address Evolving SARS-CoV-2 Variants. Dr. Hauser will discuss the importance of T cell immunity to conserved viral epitopes amid the backdrop of rapid viral evolution.

• Genetic Vaccine Development for Infectious Disease Summit, Boston, MA, May 24-26

On May 26, Don Diamond, PhD, professor in City of Hope’s Department of Hematology & Hematopoietic Transplantation, and the lead original developer of GeoVax’s vaccine against COVID-19 (GEO-CM04S1, formerly known as COH04S1) currently being evaluated in two Phase 2 clinical trials, will deliver a presentation titled, Conception, Construction, Pre-Clinical & Clinical Testing of COH04S1 Vaccine with Activity Against SARS-CoV-2.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer using novel proprietary platforms. GeoVax’s product pipeline includes two ongoing Phase 2 clinical trials of GEO-CM04S1 (formerly COH04S1) for COVID-19 as a universal booster vaccine to mRNA vaccines authorized by the U.S. Food and Drug Administration (FDA) and as a primary vaccine for use in immunocompromised patients. In addition to GEO-CM04S1 for COVID-19, GeoVax is developing GEO-CM02 as a pan-coronavirus vaccine. The Company is also conducting a Phase 1/2 clinical trial of Gedeptin® for treatment of head and neck cancer. Gedeptin® has been granted orphan drug status by the FDA. Additional research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property stands at over 70 granted or pending patent applications spread over 20 patent families.

For additional information about GeoVax, visit our website: www.geovax.com.

Contact:
GeoVax Labs, Inc.
investor@geovax.com
678-384-7220

FAQ

What is GeoVax Labs, Inc. presenting at the National Biotechnology Conference?

GeoVax Labs will have Dr. Mary Hauser present on May 11, 2022, discussing T cell immunity related to SARS-CoV-2 variants.

When is the Genetic Vaccine Development Summit where GeoVax will present?

The Genetic Vaccine Development Summit will take place from May 24-26, 2022.

Who will present at the Genetic Vaccine Development Summit for GeoVax?

Dr. Don Diamond will present on May 26, 2022, regarding the COH04S1 vaccine's development.

What clinical trials is GeoVax currently conducting for COVID-19?

GeoVax is conducting two Phase 2 clinical trials for its GEO-CM04S1 vaccine, aimed at both boosting and primary vaccination for COVID-19.

What innovative vaccine platforms does GeoVax utilize?

GeoVax employs proprietary platforms to develop vaccines and immunotherapies against infectious diseases and cancer.